| Case Number | 9634 |
| Request Date | 15/09/2023 |
| Completion Date | 02/10/2023 |
Details of the Request
1. How many of the following intra-vitreal injections / implants has your trust administered in the four-month period from May to August 2023:
- Aflibercept
- Bevacizumab - Avastin
- Bevacizumab - Biosimilar
- Brolucizumab
- Dexamethasone
- Faricimab
- Fluocinolone acetonide
- Ranibizumab - Lucentis (pre-filled syringes)
- Ranibizumab - Lucentis (vials)
- Ranibizumab - Ongavia
2. Please provide the number of injections / implants by eye condition for the four-month period from May to August 2023:
Details of the Response
1. How many of the following intra-vitreal injections/implants has your trust administered in the four-month period from May to August 2023:
- Aflibercept = 1596
- Bevacizumab - Avastin = 76
- Bevacizumab - Biosimilar = 0
- Brolucizumab = 0
- Dexamethasone = 75
- Faricimab = 151
- Fluocinolone acetonide = 0
- Ranibizumab - Lucentis (pre-filled syringes) = 704
- Ranibizumab - Lucentis (vials) = 0
- Ranibizumab - Ongavia = 0
2. Please provide the number of injections/implants by eye condition for the four-month period from May to August 2023:
Number of Injections / Implants: May - August 2023:
| Treatment | Wet Age-Related Macular Degeneration (wAMD) | Diabetic Macular Oedema (DMO) | Retinal Vein Occlusion (RVO) * |
| Aflibercept | 904 | 200 | 168 |
| Bevacizumab | 11 | 0 | 0 |
| Dexamethasone | 0 | 0 | 6 |
| Faricimab | 144 | 58 | 0 |
| Ranibizumab - Lucentis | 421 | 118 | 29 |
| Ranibizumab - Ongavia | 0 | 0 | 0 |
* This response includes both C-RVO and B-RVO.



